ba0001pp451 | Osteoporosis: treatment | ECTS2013
Zysset Philippe
, Pahr Dieter
, Engelke Klaus
, Genant Harry
, McClung Michael
, Kendler David
, Recknor Christopher
, Kinzl Michael
, Schwiedrzik Jakob
, Museyko Oleg
, Wang Andrea
, Libanati Cesar
Denosumab subcutaneous administration every 6 months reduced the incidence of new fractures in postmenopausal women with osteoporosis by 68% at the spine and 40% at the hip over 36 months compared with placebo in the FREEDOM study (Cummings et al., NEJM, 2009:361:756). This efficacy was supported by differential improvements from baseline in vertebral and femoral strength at 36 months (18.2 and 8.6%, respectively) estimated by an established voxel-based finit...